Compare SER & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 38.2M |
| IPO Year | 2018 | N/A |
| Metric | SER | VNRX |
|---|---|---|
| Price | $3.25 | $0.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.00 | $3.17 |
| AVG Volume (30 Days) | 15.1K | ★ 2.8M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $116,000.00 | ★ $1,472,007.00 |
| Revenue This Year | $134.46 | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $3.12 | $0.27 |
| 52 Week High | $7.92 | $0.94 |
| Indicator | SER | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 31.94 |
| Support Level | $3.15 | $0.28 |
| Resistance Level | $4.26 | $0.31 |
| Average True Range (ATR) | 0.25 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.09 | 3.40 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.